Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2011

View Archived Issues

GlaxoSmithKline discloses first-in-human data on GSK-2126458 and GSK-2141795

Roche presents new inhibitors of the Mdm2-p53 interaction

Novel hepatocyte growth factor receptor inhibitors patented

Phase II extension trial evaluates continued E-5501 treatment of thrombocytopenia

Phase II ARQ-197 trial assesses safety and efficacy in relapsed/refractory non-CNS germ cell tumors

Pilot study supports tolerability of AC-480 in patients with recurrent malignant glioma

Receptos designs new lysophospholipid S1P1 receptor agonists

Novel chemokine CXCR4 receptor ligands patented

Zealand Pharma and Boehringer Ingelheim join to advance new drugs for type 2 diabetes and obesity

Tradjenta tablets launched in U.S. for type 2 diabetes

BMT-4-159 is a new 17-beta-HSD 5 inhibitor with potential to treat prostate cancer

Orexo completes first clinical study of OX-27 for breakthrough cancer pain

Kareus Therapeutics and Quintiles enter strategic alliance

Data presented from two phase II trials of BCX-4208 with/without allopurinol in gout

AC-201 to enter phase IIb trial in type 2 diabetes

Servier holds option to acquire full Ampakine rights from Cortex Pharmaceuticals

Pronova BioPharma prepares to submit application for PRC-4016 trial in mixed dyslipidemia

New glycogen synthase activators presented

BiondVax reports phase IIa data on Multimeric-001 universal flu vaccine

Sanofi and Audion Therapeutics to develop treatments for hearing loss

MP4OX enters phase IIb trial in patients with trauma and lactic acidosis due to hemorrhagic shock

FDA accepts IntelGenx's resubmission of CPI-300 NDA

Istodax approved in U.S. as therapy for previously treated patients with peripheral T-cell lymphoma

Durasert-based latanoprost delivery implant enters phase I/II trial in patients with elevated IOP

FDA committee to review Seattle Genetic's Adcetris BLAs in July

Bardoxolone methyl enters pivotal trial in patients with chronic kidney disease and type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...